Tag Archive for: Sanofi

A reanalysis of data from the FOURIER trial found a higher risk of cardiovascular death associated with Amgen’s injectable cholesterol therapeutic Repatha (evolocumab), according to a study published last month.

Drugmakers including Pfizer Inc., GlaxoSmithKline PLC, Bristol Myers Squibb, AstraZeneca PLC, and Sanofi SA plan to raise prices in the United States on more than 350 unique drugs in early January, according to data analyzed by healthcare research firm 3 Axis Advisors.

Sanofi and Innate Pharma expand their longtime collaboration by licensing up to three NK cells engager programs in cancer immunotherapy valued at more than $1.4 billion.

Multimillion-dollar gene therapies being tested for sickle cell disease will be cost-effective in the United States if health disparities tied in part to decreased access to healthcare are taken into account, researchers said at a meeting of blood-disease specialists.

A review of the latest executive moves in the pharma industry over the past several months.

Japanese company Takeda’s dengue vaccine was authorized for use in the European Union on Thursday, making it the second approved vaccine for the mosquito-borne disease that causes millions of infections annually.

France’s Haute Autorite de Sante public health body advised the government not to use Valneva’s VLA2001 COVID-19 vaccine as part of its wider vaccination strategy, although two rival products should be included as booster shots.

Shares of GSK and Sanofi surged on Wednesday, adding more than $20 billion in combined value in early trade following the dismissal of thousands of U.S. lawsuits claiming that the heartburn drug Zantac caused cancer.

And then there were two. Janssen (Johnson & Johnson) is no longer in the running to acquire rare disease player Horizon Therapeutics, the company announced Saturday. 

While acquiring Horizon would add a mixed portfolio of specialty drugs to Sanofi’s roster, it would not address the French company’s need to develop its drug pipeline and improve its productivity from research and development, analysts say.